Surgical specialties
Learned societies
See also
List of Surgery-related fields
Notes
References
Further reading
Bartolo, M., Bargellesi, S., Castioni, C. A., Intiso, D., Fontana, A., Copetti, M., Scarponi, F.,  Bonaiuti, D., & Intensive Care and Neurorehabilitation Italian Study Group (2017). Mobilization in early rehabilitation in intensive care unit patients with severe acquired brain injury: An observational study. Journal of rehabilitation medicine, 49(9), 715–722. https://doi.org/10.2340/16501977-2269
Ni, C.-yan, Wang, Z.-hong, Huang, Z.-ping, Zhou, H., Fu, L.-juan, Cai, H., Huang,   X.-xuan, Yang, Y., Li, H.-fen, & Zhou, W.-ping. (2018). Early enforced mobilization after liver resection: A prospective randomized controlled trial. International Journal of Surgery, 54, 254–258. https://doi.org/10.1016/j.ijsu.2018.04.060
Lei, Y. T., Xie, J. W., Huang, Q., Huang, W., & Pei, F. X. (2021). Benefits of early   ambulation within 24 h after total knee arthroplasty: a multicenter retrospective cohort study in China. Military Medical Research, 8(1), 17. https://doi.org/10.1186/s40779-021-00310-x
Stethen, T. W., Ghazi, Y. A., Heidel, R. E., Daley, B. J., Barnes, L., Patterson, D., &   McLoughlin, J. M. (2018). Walking to recovery: the effects of missed ambulation events on postsurgical recovery after bowel resection. Journal of gastrointestinal oncology, 9(5), 953–961. 10.21037/jgo.2017.11.05
Yakkanti, R. R., Miller, A. J., Smith, L. S., Feher, A. W., Mont, M. A., & Malkani, A. L. (2019). Impact of early mobilization on length of stay after primary total knee arthroplasty. Annals of translational medicine, 7(4), 69. https://doi.org/10.21037/atm.2019.02.02
Cytisine analogs led to varenicline at Pfizer.Varenicline received a "priority review" by the US FDA in February 2006, shortening the usual ten-month review period to six months because of its demonstrated effectiveness in clinical trials and perceived lack of safety issues. The agencys approval of the drug came on May 11, 2006. On September 29, 2006, it was approved for sale in the European Union.On September 16, 2021, Pfizer announced a recall of "all lots of its anti-smoking treatment, Chantix [Varenicline], due to high levels of cancer-causing agents called nitrosamines in the pills". This followed a July 2, 2021 announcement by the FDA that it was "alerting patients and health care professionals to Pfizers voluntary recall of nine lots of the smoking cessation drug" and further recalls by Pfizer on July 19 and Aug. 8. On June 24, Pfizer had paused distribution of Chantix worldwide; "[t]he distribution halt [wa]s out of an abundance of caution, pending further testing, the company said in an email. According to the Pfizer Inc. 2020 Form 10-K Annual Report, high-revenue products by the company include[d] Chantix/Champix (varenicline) to treat nicotine addiction, [which] had $919 million in 2020 revenues.In October 2021, US FDA approved Oyster Point Pharma to market Tyrvaya as a new route of varenicline administration through nasal spray for the treatment of dry eye disease. References
External links
"Varenicline". Drug Information Portal. U.S. National Library of Medicine.